

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	09/911,703	Group Art Unit:	1644
Confirmation No.:	4927	Examiner:	R. Schwadron
Filed:	25 July 2001		
Applicant:	Darrell R. ANDERSON et al.		
For:	Anti-CD20 Antibodies (as amended)		

Mail Stop **AF**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY UNDER 37 C.F.R. § 1.116

Sir:

This communication responds to the final Office action mailed 29 December 2006, setting a three month period for response. This reply is filed within the stated period and is therefore timely.

This amendment, together with the submissions that accompany it, cancels claims and complies with formal requirements set forth in the final Office action (§ 1.116(b)(1)). Evidence and arguments presented with this reply are necessary to address issues raised for the first time in the final Office action, and were thus were not earlier presented (§ 1.116(b)(3)). Accordingly, applicant requests that the examiner enter this reply and reconsider the outstanding grounds of rejections in view of the amendments and remarks set forth below.

Applicant believes that no fee is due in connection with this reply. Any fee that may be due should be charged to our Deposit Account No. 18-1260. Applicant specifically requests that the Director charge the fee for the concurrently-filed terminal disclaimer (\$130, § 1.20(d)) to that deposit account.